Publicaciones científicas
Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice
Carolina Perdomo 1 , Paola D'Ingianna 2 , Javier Escalada 3 , Salvatore Petta 2 , Manuel Romero Gómez 4 , Javier Ampuero 5
Non-alcoholic fatty liver disease (NAFLD) is a clinical-pathological condition that encompasses a wide range of liver damage not caused by chronic alcohol consumption. It ranges from steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis, in the absence of other etiologies.
The prevalence of NAFLD has increased considerably over the last years due to the current lifestyle (unhealthy diet and sedentarism). Besides, it is associated with metabolic risk factors such as obesity, arterial hypertension, dyslipidemia, and type 2 diabetes mellitus.
Given the poor prognosis of NAFLD patients showing advanced disease, a practical therapeutic approach is mandatory to halt its natural history. However, no licensed drugs are approved to date. Nowadays, we are attending to a race to find the first drug able to stop the incidence of the NAFLD and reverse the disease in patients with further stages.
Meanwhile, the management of the metabolic overload of NAFLD, including weight loss, cardiovascular protection, insulin sensitization, and lipid reduction, is the only strategy to improve the hepatic and extra-hepatic outcomes.
In this review, we aim to describe the management of the main metabolic disorders related to NAFLD, such as type 2 diabetes mellitus, arterial hypertension, and dyslipidemia.
CITA DEL ARTÍCULO Pol Arch Intern Med. 2020 Jul 14.doi: 10.20452/pamw.15510
Nuestros autores
